Insider · CIK 1189014
Christine A Poon
- Director at Regeneron Pharmaceuticals REGN: 2 buys, 45 sales
- Director at Neurocrine Biosciences NBIX: 0 buys, 0 sales
- Director at Prudential Financial PRU: 1 buys, 0 sales
- Director at Sherwin Williams SHW: 0 buys, 0 sales
- Vice Chairman at Johnson & Johnson JNJ: 0 buys, 0 sales
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys3
Open-market sales45
Bought$339K
Sold$78.2M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 7,830 sh at $376.69 The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.9M | 13,049 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 218 sh at $966.74 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $211K | 12,831 −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 772 sh at $967.38 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $747K | 12,059 −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 2,499 sh at $968.58 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.4M | 9,560 −21% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 3,203 sh at $969.50 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $3.1M | 6,357 −34% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 937 sh at $970.51 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $909K | 5,420 −15% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 201 sh at $971.31 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $195K | 5,219 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| May 21, 2026 | Neurocrine Biosciences NBIX | Option exercise 3,318 sh 2 days after a Form 144 notice of a planned insider sale filed May 19, 2026. | 4,753 | 2 days after a Form 144 notice of a planned insider sale filed May 19, 2026. | |
| May 12, 2026 | Prudential Financial PRU | Option exercise 1,765 sh The same day as the company's 8-K filed May 12, 2026. | 13,348 | The same day as the company's 8-K filed May 12, 2026. | |
| May 12, 2026 | Prudential Financial PRU | Returned to company 1,765 sh at $102.58 The same day as the company's 8-K filed May 12, 2026. | $181K | 11,583 | The same day as the company's 8-K filed May 12, 2026. |
| Jan 2, 2026 | Regeneron Pharmaceuticals REGN | Award 155 sh 43 days after a Form 144 notice of a planned insider sale filed Nov 20, 2025. | 5,219 | 43 days after a Form 144 notice of a planned insider sale filed Nov 20, 2025. | |
| Oct 30, 2025 | Regeneron Pharmaceuticals REGN | Option exercise 2,712 sh at $520.01 1 day after a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $1.4M | 5,064 | 1 day after a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Option exercise 6,500 sh at $520.01 The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $3.4M | 8,852 | The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 650 sh at $652.68 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $424K | 8,202 −7% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 2,735 sh at $653.50 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $1.8M | 5,467 −33% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 1,915 sh at $654.42 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $1.3M | 3,552 −35% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 100 sh at $655.10 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $66K | 3,452 −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 712 sh at $656.50 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $467K | 2,740 −21% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| Oct 29, 2025 | Regeneron Pharmaceuticals REGN | Sold 388 sh at $657.29 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. | $255K | 2,352 −14% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Oct 29, 2025. |
| May 22, 2025 | Neurocrine Biosciences NBIX | Option exercise 1,435 sh 8 days after the company's SCHEDULE 13G filed May 14, 2025. | 1,435 | 8 days after the company's SCHEDULE 13G filed May 14, 2025. | |
| May 13, 2025 | Prudential Financial PRU | Option exercise 1,321 sh The same day as the company's 424B2 filed May 13, 2025. | 12,904 | The same day as the company's 424B2 filed May 13, 2025. | |
| May 13, 2025 | Prudential Financial PRU | Returned to company 1,321 sh at $107.40 The same day as the company's 424B2 filed May 13, 2025. | $142K | 11,583 | The same day as the company's 424B2 filed May 13, 2025. |
| Apr 4, 2025 | Sherwin Williams SHW | Award 4 sh at $338.25 43 days after the company's 10-K filed Feb 20, 2025. | $1K | 2,573 | 43 days after the company's 10-K filed Feb 20, 2025. |
| Feb 18, 2025 | Sherwin Williams SHW | Award 517 sh 84 days after a Form 144 notice of a planned insider sale filed Nov 26, 2024. | 12,386 | 84 days after a Form 144 notice of a planned insider sale filed Nov 26, 2024. | |
| Jan 3, 2025 | Sherwin Williams SHW | Award 25 sh at $335.00 38 days after a Form 144 notice of a planned insider sale filed Nov 26, 2024. | $8K | 2,563 | 38 days after a Form 144 notice of a planned insider sale filed Nov 26, 2024. |
| Jan 2, 2025 | Regeneron Pharmaceuticals REGN | Award 166 sh 63 days after the company's 10-Q filed Oct 31, 2024. | 2,352 | 63 days after the company's 10-Q filed Oct 31, 2024. | |
| Dec 20, 2024 | Regeneron Pharmaceuticals REGN | Other 14 sh 50 days after the company's 10-Q filed Oct 31, 2024. | 2,186 | 50 days after the company's 10-Q filed Oct 31, 2024. | |
| Oct 4, 2024 | Sherwin Williams SHW | Award 23 sh at $372.47 338 days after the company's 8-K filed Nov 1, 2023. | $8K | 2,534 | 338 days after the company's 8-K filed Nov 1, 2023. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Option exercise 10,838 sh at $413.33 14 days after the company's 10-Q filed Aug 1, 2024. | $4.5M | 13,010 | 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 1,012 sh at $1,155.72 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $1.2M | 11,998 −8% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 2,368 sh at $1,156.30 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $2.7M | 9,630 −20% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 1,560 sh at $1,157.33 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $1.8M | 8,070 −16% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 212 sh at $1,158.02 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $246K | 7,858 −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 5,352 sh at $1,159.56 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $6.2M | 2,506 −68% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 234 sh at $1,160.45 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $272K | 2,272 −9% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 15, 2024 | Regeneron Pharmaceuticals REGN | Sold 100 sh at $1,161.32 The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. | $116K | 2,172 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. 14 days after the company's 10-Q filed Aug 1, 2024. |
| Jul 5, 2024 | Sherwin Williams SHW | Award 29 sh at $295.50 247 days after the company's 8-K filed Nov 1, 2023. | $8K | 2,506 | 247 days after the company's 8-K filed Nov 1, 2023. |
| May 9, 2024 | Prudential Financial PRU | Option exercise 1,935 sh | 13,518 | ||
| May 9, 2024 | Prudential Financial PRU | Returned to company 1,935 sh at $117.95 | $228K | 11,583 | |
| Apr 5, 2024 | Sherwin Williams SHW | Award 25 sh at $331.56 156 days after the company's 8-K filed Nov 1, 2023. | $8K | 2,471 | 156 days after the company's 8-K filed Nov 1, 2023. |
| Feb 13, 2024 | Sherwin Williams SHW | Award 594 sh 104 days after the company's 8-K filed Nov 1, 2023. | 11,869 | 104 days after the company's 8-K filed Nov 1, 2023. | |
| Jan 5, 2024 | Sherwin Williams SHW | Award 28 sh at $296.96 65 days after the company's 8-K filed Nov 1, 2023. | $8K | 2,441 | 65 days after the company's 8-K filed Nov 1, 2023. |
| Jan 2, 2024 | Regeneron Pharmaceuticals REGN | Award 135 sh The same day as a Form 144 notice of a planned insider sale filed Jan 2, 2024. | 2,172 | The same day as a Form 144 notice of a planned insider sale filed Jan 2, 2024. | |
| Oct 6, 2023 | Sherwin Williams SHW | Award 32 sh at $253.15 73 days after the company's 10-Q filed Jul 25, 2023. | $8K | 2,407 | 73 days after the company's 10-Q filed Jul 25, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Option exercise 12,280 sh at $273.67 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $3.4M | 14,317 | 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Sold 300 sh at $837.92 The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $251K | 14,017 −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Sold 1,998 sh at $838.60 The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $1.7M | 12,019 −14% | The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Sold 3,032 sh at $839.45 The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $2.5M | 8,987 −25% | The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Sold 6,450 sh at $840.65 The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $5.4M | 2,537 −72% | The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Aug 23, 2023 | Regeneron Pharmaceuticals REGN | Sold 500 sh at $841.05 The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. | $421K | 2,037 −20% | The filing does not mark this sale as under a Rule 10b5-1 plan. 2 days after a Form 144 notice of a planned insider sale filed Aug 21, 2023. |
| Jul 7, 2023 | Sherwin Williams SHW | Award 32 sh at $257.00 73 days after the company's 10-Q filed Apr 25, 2023. | $8K | 2,370 | 73 days after the company's 10-Q filed Apr 25, 2023. |
| May 9, 2023 | Prudential Financial PRU | Option exercise 1,517 sh | 13,100 | ||
| May 9, 2023 | Prudential Financial PRU | Returned to company 1,517 sh at $81.50 | $124K | 11,583 | |
| Apr 10, 2023 | Sherwin Williams SHW | Award 36 sh at $223.68 74 days after the company's 8-K filed Jan 26, 2023. | $8K | 2,333 | 74 days after the company's 8-K filed Jan 26, 2023. |
| Feb 14, 2023 | Sherwin Williams SHW | Award 711 sh 19 days after the company's 8-K filed Jan 26, 2023. | 11,275 | 19 days after the company's 8-K filed Jan 26, 2023. | |
| Jan 6, 2023 | Sherwin Williams SHW | Award 35 sh at $232.66 73 days after the company's 8-K filed Oct 25, 2022. | $8K | 2,290 | 73 days after the company's 8-K filed Oct 25, 2022. |
| Jan 3, 2023 | Regeneron Pharmaceuticals REGN | Award 165 sh | 2,037 | ||
| Oct 7, 2022 | Sherwin Williams SHW | Award 39 sh at $209.43 | $8K | 2,250 | |
| Aug 9, 2022 | Regeneron Pharmaceuticals REGN | Option exercise 15,000 sh at $177.82 | $2.7M | 16,872 | |
| Aug 9, 2022 | Regeneron Pharmaceuticals REGN | Sold 6,814 sh at $620.47 The filing does not mark this sale as under a Rule 10b5-1 plan. | $4.2M | 10,058 −40% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 9, 2022 | Regeneron Pharmaceuticals REGN | Sold 8,186 sh at $621.27 The filing does not mark this sale as under a Rule 10b5-1 plan. | $5.1M | 1,872 −81% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Jul 8, 2022 | Sherwin Williams SHW | Award 34 sh at $237.91 | $8K | 2,205 | |
| May 10, 2022 | Prudential Financial PRU | Option exercise 1,494 sh | 13,077 | ||
| May 10, 2022 | Prudential Financial PRU | Returned to company 1,494 sh at $104.25 | $156K | 11,583 | |
| Apr 8, 2022 | Sherwin Williams SHW | Award 31 sh at $264.59 | $8K | 2,167 | |
| Feb 15, 2022 | Sherwin Williams SHW | Award 529 sh | 10,564 | ||
| Jan 7, 2022 | Sherwin Williams SHW | Award 25 sh at $327.94 | $8K | 2,131 | |
| Jan 3, 2022 | Regeneron Pharmaceuticals REGN | Award 191 sh | 1,872 | ||
| Oct 8, 2021 | Sherwin Williams SHW | Award 27 sh at $291.45 | $8K | 2,103 | |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Option exercise 15,000 sh at $57.11 | $857K | 16,681 | |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 100 sh at $662.62 The filing does not mark this sale as under a Rule 10b5-1 plan. | $66K | 16,581 −1% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 2,260 sh at $663.51 The filing does not mark this sale as under a Rule 10b5-1 plan. | $1.5M | 14,321 −14% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 700 sh at $664.42 The filing does not mark this sale as under a Rule 10b5-1 plan. | $465K | 13,621 −5% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 538 sh at $665.33 The filing does not mark this sale as under a Rule 10b5-1 plan. | $358K | 13,083 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 1,118 sh at $666.70 The filing does not mark this sale as under a Rule 10b5-1 plan. | $745K | 11,965 −9% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 2,150 sh at $667.37 The filing does not mark this sale as under a Rule 10b5-1 plan. | $1.4M | 9,815 −18% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 603 sh at $668.33 The filing does not mark this sale as under a Rule 10b5-1 plan. | $403K | 9,212 −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 2,235 sh at $669.59 The filing does not mark this sale as under a Rule 10b5-1 plan. | $1.5M | 6,977 −24% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 3,447 sh at $670.48 The filing does not mark this sale as under a Rule 10b5-1 plan. | $2.3M | 3,530 −49% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 1,737 sh at $671.49 The filing does not mark this sale as under a Rule 10b5-1 plan. | $1.2M | 1,793 −49% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 27, 2021 | Regeneron Pharmaceuticals REGN | Sold 112 sh at $672.27 The filing does not mark this sale as under a Rule 10b5-1 plan. | $75K | 1,681 −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Jul 2, 2021 | Sherwin Williams SHW | Award 28 sh at $274.96 | $8K | 2,072 | |
| May 11, 2021 | Prudential Financial PRU | Option exercise 2,933 sh | 14,516 | ||
| May 11, 2021 | Prudential Financial PRU | Returned to company 2,933 sh at $104.91 | $308K | 11,583 | |
| Apr 5, 2021 | Sherwin Williams SHW | Award 31 sh at $253.36 | $8K | 2,040 | |
| Feb 16, 2021 | Sherwin Williams SHW | Award 221 sh | 3,345 | ||
| Jan 8, 2021 | Sherwin Williams SHW | Award 11 sh at $727.84 | $8K | 668 | |
| Jan 4, 2021 | Regeneron Pharmaceuticals REGN | Award 248 sh | 1,681 | ||
| Oct 2, 2020 | Sherwin Williams SHW | Award 11 sh at $688.84 | $8K | 656 | |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 15,000 sh at $33.42 | $501K | 16,433 | |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 25,000 sh at $25.45 | $636K | 41,433 | |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 177 sh at $598.91 The filing does not mark this sale as under a Rule 10b5-1 plan. | $106K | 41,256 −<1% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 5,730 sh at $599.67 The filing does not mark this sale as under a Rule 10b5-1 plan. | $3.4M | 35,526 −14% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 12,490 sh at $600.44 The filing does not mark this sale as under a Rule 10b5-1 plan. | $7.5M | 23,036 −35% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 8,011 sh at $601.53 The filing does not mark this sale as under a Rule 10b5-1 plan. | $4.8M | 15,025 −35% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 12,899 sh at $602.39 The filing does not mark this sale as under a Rule 10b5-1 plan. | $7.8M | 2,126 −86% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 28, 2020 | Regeneron Pharmaceuticals REGN | Sold 693 sh at $603.20 The filing does not mark this sale as under a Rule 10b5-1 plan. | $418K | 1,433 −33% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Jul 6, 2020 | Sherwin Williams SHW | Award 13 sh at $588.25 | $8K | 643 | |
| May 12, 2020 | Prudential Financial PRU | Option exercise 1,607 sh | 13,190 | ||
| May 12, 2020 | Prudential Financial PRU | Returned to company 1,607 sh at $54.26 | $87K | 11,583 | |
| Apr 3, 2020 | Sherwin Williams SHW | Award 19 sh at $429.42 | $8K | 629 | |
| Feb 18, 2020 | Sherwin Williams SHW | Award 277 sh | 3,124 | ||
| Jan 3, 2020 | Sherwin Williams SHW | Award 16 sh at $567.91 | $9K | 608 | |
| Jan 2, 2020 | Regeneron Pharmaceuticals REGN | Award 320 sh | 1,433 | ||
| Oct 4, 2019 | Sherwin Williams SHW | Award 18 sh at $549.10 | $10K | 591 | |
| Jul 5, 2019 | Sherwin Williams SHW | Award 18 sh at $463.88 | $8K | 572 | |
| May 8, 2019 | Prudential Financial PRU | Option exercise 1,558 sh | 13,141 | ||
| May 8, 2019 | Prudential Financial PRU | Returned to company 1,558 sh at $100.80 | $157K | 11,583 | |
| Apr 5, 2019 | Sherwin Williams SHW | Award 20 sh at $449.23 | $9K | 553 | |
| Feb 12, 2019 | Sherwin Williams SHW | Award 409 sh | 2,847 | ||
| Jan 4, 2019 | Sherwin Williams SHW | Award 23 sh at $390.47 | $9K | 531 | |
| Jan 2, 2019 | Regeneron Pharmaceuticals REGN | Award 323 sh | 1,113 | ||
| Oct 5, 2018 | Sherwin Williams SHW | Award 18 sh at $440.63 | $8K | 504 | |
| Jul 6, 2018 | Sherwin Williams SHW | Award 20 sh at $409.87 | $8K | 485 | |
| May 8, 2018 | Prudential Financial PRU | Option exercise 1,431 sh | 13,014 | ||
| May 8, 2018 | Prudential Financial PRU | Returned to company 1,431 sh at $100.10 | $143K | 11,583 | |
| Apr 6, 2018 | Sherwin Williams SHW | Award 19 sh at $395.69 | $8K | 464 | |
| Feb 13, 2018 | Sherwin Williams SHW | Award 361 sh | 2,438 | ||
| Jan 5, 2018 | Sherwin Williams SHW | Award 19 sh at $419.79 | $8K | 444 | |
| Oct 6, 2017 | Sherwin Williams SHW | Award 21 sh at $379.83 | $8K | 424 | |
| Jul 7, 2017 | Sherwin Williams SHW | Award 24 sh at $349.41 | $8K | 402 | |
| May 9, 2017 | Prudential Financial PRU | Option exercise 2,006 sh | 13,589 | ||
| May 9, 2017 | Prudential Financial PRU | Returned to company 2,006 sh at $107.88 | $216K | 11,583 | |
| Apr 7, 2017 | Sherwin Williams SHW | Award 26 sh at $312.39 | $8K | 378 | |
| Feb 14, 2017 | Sherwin Williams SHW | Award 539 sh | 2,077 | ||
| Jan 6, 2017 | Sherwin Williams SHW | Award 30 sh at $277.55 | $8K | 351 | |
| Oct 7, 2016 | Sherwin Williams SHW | Award 29 sh at $266.36 | $8K | 320 | |
| Jul 1, 2016 | Sherwin Williams SHW | Award 26 sh at $294.87 | $8K | 290 | |
| May 10, 2016 | Prudential Financial PRU | Option exercise 1,795 sh | 11,583 | ||
| Apr 1, 2016 | Sherwin Williams SHW | Award 28 sh at $283.97 | $8K | 263 | |
| Feb 16, 2016 | Sherwin Williams SHW | Award 466 sh | 1,538 | ||
| Jan 8, 2016 | Sherwin Williams SHW | Award 32 sh at $243.96 | $8K | 235 | |
| Oct 2, 2015 | Sherwin Williams SHW | Award 34 sh at $227.98 | $8K | 202 | |
| Aug 12, 2015 | Regeneron Pharmaceuticals REGN | Sold 100 sh at $564.16 The filing does not mark this sale as under a Rule 10b5-1 plan. | $56K | 802 −11% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 12, 2015 | Regeneron Pharmaceuticals REGN | Sold 12 sh at $564.17 The filing does not mark this sale as under a Rule 10b5-1 plan. | $7K | 790 −1% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Aug 11, 2015 | Regeneron Pharmaceuticals REGN | Option exercise 470 sh at $273.67 | $129K | 1,125 | |
| Aug 11, 2015 | Regeneron Pharmaceuticals REGN | Tax withholding 223 sh at $574.57 | $128K | 902 | |
| Jul 2, 2015 | Sherwin Williams SHW | Award 28 sh at $280.24 | $8K | 167 | |
| May 12, 2015 | Prudential Financial PRU | Option exercise 1,821 sh | 9,788 | ||
| Apr 2, 2015 | Sherwin Williams SHW | Award 27 sh at $284.73 | $8K | 139 | |
| Feb 17, 2015 | Sherwin Williams SHW | Award 500 sh | 1,072 | ||
| Jan 2, 2015 | Sherwin Williams SHW | Award 26 sh at $264.40 | $7K | 112 | |
| Nov 25, 2014 | Regeneron Pharmaceuticals REGN | Bought 400 sh at $410.00 | $164K | 655 +157% | |
| Oct 3, 2014 | Sherwin Williams SHW | Award 28 sh at $215.81 | $6K | 86 | |
| Jul 3, 2014 | Sherwin Williams SHW | Award 28 sh at $207.07 | $6K | 58 | |
| May 21, 2014 | Regeneron Pharmaceuticals REGN | Bought 255 sh at $291.90 Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. | $74K | 255 | Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. |
| May 13, 2014 | Prudential Financial PRU | Option exercise 1,842 sh | 7,967 | ||
| May 9, 2014 | Sherwin Williams SHW | Award 30 sh at $197.36 | $6K | 30 | |
| Apr 16, 2014 | Sherwin Williams SHW | Award 552 sh | 572 | ||
| Feb 13, 2009 | Johnson & Johnson JNJ | Option exercise 17,141 sh | 61,942 | ||
| Feb 13, 2009 | Johnson & Johnson JNJ | Tax withholding 6,231 sh at $57.31 | $357K | 55,711 | |
| Feb 11, 2009 | Prudential Financial PRU | Option exercise 4,775 sh at $25.30 | $121K | 6,125 | |
| Dec 31, 2008 | Johnson & Johnson JNJ | Other 2 sh | 178 | ||
| Sep 30, 2008 | Johnson & Johnson JNJ | Other 1 sh | 176 | ||
| May 30, 2008 | Johnson & Johnson JNJ | Other 1 sh | 175 | ||
| May 14, 2008 | Prudential Financial PRU | Bought 1,350 sh at $74.35 Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. | $100K | 1,350 | Their first shares, by the holdings the Form 4 states. Their first open-market buy here in SEC Tracker's records. |
| Mar 31, 2008 | Johnson & Johnson JNJ | Other 1 sh | 174 | ||
| Dec 31, 2007 | Johnson & Johnson JNJ | Other 1 sh | 173 | ||
| Sep 28, 2007 | Johnson & Johnson JNJ | Other 1 sh | 172 | ||
| Jun 29, 2007 | Johnson & Johnson JNJ | Other 1 sh | 171 | ||
| Feb 28, 2007 | Johnson & Johnson JNJ | Other 1 sh | 170 | ||
| Dec 29, 2006 | Johnson & Johnson JNJ | Other 1 sh | 169 | ||
| Sep 29, 2006 | Johnson & Johnson JNJ | Other 1 sh | 168 | ||
| Jun 30, 2006 | Johnson & Johnson JNJ | Other 1 sh | 167 | ||
| Mar 31, 2006 | Johnson & Johnson JNJ | Other 1 sh | 166 | ||
| Dec 30, 2005 | Johnson & Johnson JNJ | Other 1 sh | 165 | ||
| Sep 30, 2005 | Johnson & Johnson JNJ | Other 1 sh | 164 | ||
| Jun 30, 2005 | Johnson & Johnson JNJ | Other 1 sh | 163 | ||
| Dec 31, 2004 | Johnson & Johnson JNJ | Other 1 sh | 162 | ||
| Sep 30, 2004 | Johnson & Johnson JNJ | Other 1 sh | 161 | ||
| May 31, 2004 | Johnson & Johnson JNJ | Other 9 sh | 160 | ||
| Mar 31, 2004 | Johnson & Johnson JNJ | Other 35 sh | 151 | ||
| Jan 30, 2004 | Johnson & Johnson JNJ | Other 17 sh | 116 |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.
Data on this page was fetched . The filing on SEC.gov is the record.